The effects of antithymocyte globulin (ATG) on the endothelial glycocalyx in kidney transplant recipients

The effects of antithymocyte globulin (ATG) on the endothelial glycocalyx in kidney transplant recipients - ATG/endothelial glycocalyx/kidney transplantation

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON34735

Enrollment

Registered

2010-05-19

Start date

2010-02-01

Completion date

Unknown

Last updated

2024-05-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

endothelial glycocalyx and atherosclerosis

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Female or male, age between 18 and 70 years Kidney transplant recipient ATG therapy because of an allograft rejection Given written informed consent

Exclusion criteria

Exclusion criteria: Smoking Diabetes Mellitus

Design outcomes

Primary

Measure	Time frame
The thickness of the endothelial glycocalyx in kidney transplant recipients before and after ATG therapy.	—

Secondary

Measure	Time frame
The following parameters will be measured: - Glycocalyx constituents and glycocalyx regulating enzymes: hyaluronan, heparan sulfate, syndican-1, hyaluronidase en heparanase - IL-6, CRP	—

Countries

Netherlands

Outcome results